Positron Emission Tomography (PET) is a significant advance in cancer imaging with great potential for optimizing radiation therapy (RT) treatment planning and thereby improving outcomes for patients. The use of PET and PET/CT in RT planning was 
Introduction
Positron Emission Tomography (PET) scanning is a significant advance in cancer imaging [1] . When combined with structural imaging, such as computed tomography (CT), 18 F-fluorodeoxyglucose (FDG)-PET provides the best available information on tumor extent for many common cancers [2] . Significant experience with PET in radiation therapy (RT) planning is largely confined to academic centres. The Applied Radiation Biology and Radiotherapy (ARBR) and Nuclear Medicine (NM) sections of the International Atomic Energy Authority (IAEA) assembled a group of experts in radiation oncology and nuclear medicine to review the use of PET in RT planning. RT plays a central role in the management of many potentially-curable malignancies, often in combination with other modalities. In curative RT, the target volume of tissue irradiated to high dose must encompass the entire tumor and any microscopic extensions of disease but should be kept as small as possible to minimize damage to normal tissues. Advances in computer assisted 3D planning such as three-dimensional conformal radiotherapy (3DCRT), intensity modulated radiation therapy (IMRT) [3] and image guided radiation therapy (IGRT) facilitate delivery of higher radiation doses to the tumor [4, 5] and increase normal tissue sparing. To exploit these advances, accurate target delineation is essential. PET-based staging has proven to be more accurate than non-PET staging for many cancers and it is therefore rational to use PET for RT planning in situations where it is known to more accurate than conventional imaging. However, high quality evidence, specifically supporting the use of PET in RT planning, is lacking. The potential benefits of PET in RT planning are generally inferred from studies of staging or patient selection that show the superior accuracy of PET in specific clinical situations. For many patients, a single PET scan is used for all three purposes ( staging, selection and treatment planning).
The participants in this review were therefore free to consider all data that they considered relevant to the use of PET in RT planning. Levels of evidence were not formally assessed because no high level evidence (for example randomized controlled trials) has been published on the use of PET in RT planning. In addition to explicit studies of RT planning, relevant investigations of patient selection, tumour staging, tumor movement and tumor biology were reviewed. Of all the common cancers, lung cancer has been most intensively studied with PET and a significant proportion of the published RT planning literature concerns this group of malignancies. For this reason, the use of PET in RT patients with lung cancer is considered in most detail. There is a growing body of evidence concerning the use of PET for RT planning in head and neck (H&N) tumors, esophageal tumors and lymphoma and these are each discussed briefly as they represent different challenges. There are many other cancers for which PET may play a role in RT planning but a detailed discussion of each of these is beyond the scope of this review. 
The central role of imaging in Radiation Therapy Planning

Structural Imaging
RT planning is critically dependent on imaging. Soon after its introduction in the 1980's, CT-based conformal RT (CRT) planning became a routine part of cancer management. While modalities such as magnetic resonance (MR) imaging can sometimes provide superior tumor imaging (e.g. in brain tumors [6] ), CT remains essential for dosimetry and for imaging dose-limiting normal organs. Nevertheless, structural imaging has significant limitations for imaging some tumors and lymph node metastases. These shortcomings can lead to significant interobserver variability when contouring tumors for RT [7] . Failure to encompass the tumor resulting from inadequate imaging cannot be compensated for by dose escalation [8] .
The advent of PET
With PET and PET/CT, sensitive, quantifiable and accurate molecular information on the biology and extent of many common cancers became available. PET often provides superior sensitivity, specificity and accuracy, compared to conventional staging. With the increasing availability of integrated PET/CT [9] exciting new possibilities now exist for RT planning [10] . Some of the most important include: to target volumes could potentially be made be made during a treatment course [11, 12] 
PET Radiopharmaceuticals
The scope for developing new PET tracers is vast, but currently only a few radiopharmaceuticals have the combination of high tumor uptake and favorable pharmacokinetics required to provide the high sensitivity and specificity at low cost needed for tumor imaging in busy clinical settings in radiation oncology.
Flourodeoxyglucose
Many malignancies have higher uptake of FDG than nearby normal tissues [13] This allows FDG-PET to image them, although FDG uptake is not cancerspecific. Uptake of FDG in tumors is affected by a range of factors, including tumour 7 Mac Manus MP et al PET in Radiation Therapy Planning blood flow [14] , activity of glucose transporters [15] and hexokinase, and by glucose consumption [16] .
FDG-PET is invaluable in many cancers for differential-diagnosis, staging, evaluation of therapeutic response and for restaging. FDG-PET is superior to CT for assessment of response to RT-CHT in non-small cell lung cancer (NSCLC) and CHT response assessment in the Hodgkin and non-Hodgkin lymphomas. PET-assisted staging is more accurate than conventional staging in a wide range of cancers commonly treated with RT. For these cancers it is rational to use FDG-PET/CT [17] for RT planning.
Other Radiopharmaceuticals
The amino acid 11 C-methionine [18] 
Target volume definition with PET/CT: General Principles
Most published RT planning studies involve FDG and NSCLC is the most commonly studied cancer [43] . PET dramatically reduces the extreme variability that A rigorous visual contouring protocol using predefined widow and colour settings and with input from the nuclear medicine physician can give highly reproducible results in NSCLC. This method was used in a prospective study of RT planning in esophageal cancer [46] . Visual planning methodology relies on human intelligence and experience to recognise various processes that lead to physiological uptake of FDG in the human body. Nevertheless, without a carefully-designed contouring protocol, it is likely that significant variations in GTV will occur. In lung cancer, PET defined GTV's are often larger than CT-defined GTV's because PET captures the location of the tumor at all phases of the respiratory cycle [47] . Even when using a standardised software-based contouring protocol there may still be significant inter-observer variation [48] .
Target Volume definition using automated or semi-automated methods
To reduce inter-observer variability in FDG-based GTV definition, various automatic or semi-automatic methods have been proposed. These must be used with caution, because none can distinguish between FDG uptake caused by neoplastic processes and common physiological or inflammatory process. FDG uptake occurs within macrophages and granulation tissue, thymic hyperplasia, brown fat, fat necrosis, smooth muscle, skeletal muscle and cardiac muscle [49] . A true gold standard for studies of 3D or 4D tumor contouring is unavailable so careful observation of local failure patterns is essential. 
SUV-based contouring
Background Cut-off
Another automated approach involves defining a cut-off with respect to the background and contouring the region with intensity above the cut-off (e.g. intensity greater than three standard deviations above the background level or a SUV above 2.5). This approach is independent of heterogeneity of lesional tracer uptake, which could hamper the application of threshold methods. The assessment of activity in the lesion and in the background is strongly affected by statistical fluctuations.
Furthermore, the robustness of the contour definition may also be affected by statistical noise. Three-dimensional (3D) PET acquisition has the potential to reduce image noise [56] compared to 2D acquisition.
Source / background algorithms
Phantom studies with varying "lesion" and background activities were conducted to derive the relationship between the true volume of homogenously-filled, (usually spherical) "lesions" and various thresholds applied to the PET images [57] [58].
Optimum thresholds varied according to the signal-to-background (S/B) ratios. This relationship is described by relatively simple equations, which render the threshold value depending on the mean background accumulation and the signal of the lesion.
Thresholds vary depending on the background definition in patient datasets. Gradientbased methods rely on a model that determines the appropriate threshold of activity on the basis of the signal-to-background ratio [59] . This method was shown to be accurate for segmenting PET images in a study of pharyngeal-laryngeal tumors [60] .
In that study, a quantitative comparison of CT, MRI, and FDG-PET showed that automatic segmentation of PET images led to tumor volumes that were significantly showed, that the application of S/B ratios led to reasonable volumes, compared with breath-expanded CT volumes. S/B algorithms may be applied to very low contrast lesions [61] . In another study auto-contouring, using source to background ratios, reduced interobserver variability compared to visual contouring and the estimated maximum tumor width was closely correlated with tumour diameter determined by pathology [62] .
The availability of multiple automated methods for contouring tumors and the absence of any reliable intercomparisons makes it difficult to recommend any single technique. However, automated methods that employ a single crude parameter, such as a particular SUV contour, are too simplistic and rigid to be useful across a wide variety of clinical scenarios and are therefore not recommended.
Tumor Movement
Tumors usually undergo physiological movement. In NSCLC movement with respiration can be dramatic [63] . Motion can be compensated for by gating, which PET/CT [71] is best but PET/CT image coregistration, ideally using fiducial markers, can be used [72] .
PET/CT should be used for RT planning in NSCLC because it more accurately images tumor extent than CT alone [73] , This is proven by a large surgical literature on the accuracy of FDG-PET in the lymph node staging of NSCLC [10, 68, 74, 75] .
Average sensitivities and specificities for FDG-PET in series with pathological confirmation have been reported as 83% and 91%, respectively, whereas for CT they were 64% and 74%, respectively [76] . Despite its higher accuracy, the limitations of PET should be remembered. The rate of false-negative lymph node station assessment (post-test probability) in NSCLC RT candidates is 5-10% [77] . In studies of solitary pulmonary nodules, a negative predictive value of about 90% is reported for FDG-PET. Some factors [78] are associated with false negative findings, including carcinoid tumors or low-grade adeno-carcinomas including broncho-alveolar carcinomas. Very small lesions (<1cm) may not be seen and, in elevated blood glucose may cause false negative FDG-PET findings. False negative scans can occur soon after CHT [79] , although a reduction in SUV is a positive prognostic factor [80] .
PET is superior to CT for response-assessment after RT. In a prospective study, PET and CT assessments performed at a median of 70 days after RT, were concordant in only 40% of cases [81] . PET response was the best predictor of survival, was strongly-correlated with patterns of failure [82] and was not confounded by normal tissue reactions [83] .
The two most important and consistent reasons for significant changes in target volumes in NSCLC with PET, cited in the literature [84] were:
1. FDG-PET significantly changed lymph node staging in the thorax, usually by showing more positive nodes than CT.
2. In cases with atelectasis, PET helped to demarcate the border between tumor and collapsed lung, allowing a smaller volume of lung to be treated [85] ( Figure 1 ).
Figure 1
Treatment of clinically uninvolved regional nodes remains controversial. [93] .
Small Cell Lung Cancer (SCLC)
SCLC is well imaged by FDG-PET [94] but few studies have directly addressed the role of PET in RT planning. Potential roles for PET include selection for radical RT-CHT, RT planning and selection of patients for prophylactic cranial irradiation (PCI). In one prospective study [95] , FDG-PET demonstrated findings consistent with extensive disease (ED) in three of 24 patients thought to have limited disease on the basis of conventional staging. FDG-PET correctly upstaged 8.3%
patients to ED. PET had a lesion-based sensitivity relative to CT of 100%. PET identified unsuspected regional nodal metastasis in 25% patients, and the RT plan was significantly altered to include the PET-positive/CT-negative nodes within the high- 
H&N cancers
Use of FDG-PET planning in H&N cancers is complex [100] . The boundaries of primary tumors can differ significantly from one another in the same patient when determined using PET, CT or MRI, making it difficult to decide where exactly to draw the GTV for RT planning. This is an especially important issue when very high does (70Gy) are delivered to lesions close to radiosensitive vital structures (e.g. brainstem or optic chiasm) and margins are often tight around tumour [101] . 
Figure 2
The greatest impact of PET on patients with H&N cancer usually results from changes in nodal status [102] and/or the detection of distant metastasis. Changes in target volume delineation occur often when FDG-PET information is added to CT [103] , mainly due to different nodal staging [101] (Figure 2 ). However FDG-PETbased RT planning is not yet ready for routine clinical practice. Recently, significant differences in GTV delineation were found between multiple observers contouring on PET/CT fused images, mainly due to the lack of a delineation protocol [104] . PET may impact delineation of nodes more than delineation of primary tumours [105] .
Careful comparison of FDG-PET, MRI and CT scans with the histopathology of resected tumour specimens shows that none of these three imaging modalities is [60] . However FDG-PET may be the most accurate of the three for the detection of head and neck cancer [106] . Tumour volume determined by FDG-PET tends to be smaller on average than the volume determined by the other modalities but most closely approximates the true tumour volume [60] . Nevertheless some tumour regions that are apparent on CT or MRI may not be imaged on PET and in these cases an exclusive reliance on PET would potentially lead to geographic miss.
Changes in RT volumes due to PET occurred in 41% of patients in one prospective study [107] . Nevertheless, despite the great promise of PET in RT planning in H&N cancer [108] , one must proceed cautiously. Uncontrolled local recurrence in the head and neck region can lead to prolonged misery and disfigurement. The results of PET studies of hypoxia imaging in H&N tumours [109] [110] [111] [112] are provocative. A significant correlation between PET hypoxia-tracer uptake and treatment response has been reported.
Lymphoma
The lymphomas are a large and heterogeneous group of diseases [113] . Early stage disease is commonly treated with "involved field" RT. PET is increasingly being used to select lymphoma patients for RT and to delineate RT fields [114] . FDG-PET is significantly more accurate in both staging [115] and treatment response assessment [116] in both Hodgkin and non-Hodgkin [117] lymphomas than conventional structural imaging. PET data are increasingly being incorporated into the RT planning process [118] . PET commonly influences RT fields in lymphoma by PET is also used to assess the response of lymphomas to CHT [120] , either at the end of therapy, or as an interim measure, after e.g. 1-3 cycles [121] [122] [123] [124] . Persistent interim tumor FDG uptake is a powerful negative prognostic factor in patients with
Hodgkin lymphoma [125] and aggressive non-Hodgkin lymphoma [122] but early complete response cannot yet identify patients who do not require RT as part of combined modality therapy. Baseline PET scans may help determine what sites will require consolidation RT.
Esophageal cancer
Combined RT-CHT, with or without surgery, is commonly used to treat esophageal carcinoma. PET can improve the accuracy of RT planning [126] .
Clinicopathological studies in patients undergoing resection show that CT portrays the radial tumor extent well. PET, however, is significantly more accurate for nodal assessment [127] , except those that lie adjacent to the esophagus, and shows the longitudinal extent of the tumor better than CT. The systematic review of PET staging for esophageal carcinoma by van Westreenen and colleagues confirmed that PET was quite accurate in its assessment of more distant lymph nodes and for the detection of regions were found to be positive on PET but negative on CT and/ or endoscopic ultrasound examination. In three of these patients (10%) the influence of the FDG-PET would have led to enlargement of the irradiated volume [129] . In another study, employing a coincidence scanner, use of fused FDG/CT scans altered the GTV in 19 of 34 patients (56%) [130] . 
